Table 1 Baseline means, effect sizes and p-values for HDRS-17-sum and individual items
From: Item-based analysis of the effects of duloxetine in depression: a patient-level post hoc study
Measure of efficacy (scoring range) | Baseline mean | s.d. | ES | p-value | ES | p-value | ES | p-value |
|---|---|---|---|---|---|---|---|---|
Week 1 | Week 6 | Week 8 | ||||||
HDRS-17-sum | 21.3 | 3.9 | 0.05 | 0.16 | 0.37 | <0.001 | 0.37 | <0.001 |
Depressed mood (0–4) | 2.7 | 0.6 | 0.20 | <0.001 | 0.46 | <0.001 | 0.44 | <0.001 |
Feelings of guilt (0–4) | 1.6 | 0.8 | 0.10 | 0.004 | 0.27 | <0.001 | 0.28 | <0.001 |
Suicidal ideation (0–4) | 0.6 | 0.8 | 0.15 | <0.001 | 0.22 | <0.001 | 0.23 | <0.001 |
Insomnia, early (0–2) | 1.2 | 0.8 | 0.05 | 0.14 | 0.06 | 0.18 | 0.09 | 0.02 |
Insomnia, middle (0–2) | 1.3 | 0.8 | −0.08 | 0.02 | 0.03 | 0.45 | 0.03 | 0.52 |
Insomnia, late (0–2) | 1.1 | 0.8 | −0.02 | 0.60 | 0.18 | <0.001 | 0.13 | 0.001 |
Work & activities (0–4) | 2.7 | 0.6 | 0.05 | 0.13 | 0.30 | <0.001 | 0.32 | <0.001 |
Retardation (0–4) | 1.0 | 0.8 | 0.04 | 0.29 | 0.29 | <0.001 | 0.22 | <0.001 |
Agitation (0–4) | 0.9 | 0.9 | 0.08 | 0.02 | 0.11 | 0.01 | 0.10 | 0.01 |
Anxiety, psychic (0–4) | 2.0 | 0.8 | 0.23 | <0.001 | 0.42 | <0.001 | 0.43 | <0.001 |
Anxiety, somatic (0–4) | 1.5 | 0.8 | -0.04 | 0.25 | 0.09 | 0.04 | 0.13 | 0.001 |
Somatic symptoms, gastrointestinal (0–2) | 0.6 | 0.6 | -0.30 | <0.001 | 0.08 | 0.09 | 0.09 | 0.03 |
Somatic symptoms, general (0–2) | 1.6 | 0.6 | −0.02 | 0.66 | 0.25 | <0.001 | 0.19 | <0.001 |
Genital symptoms (0–2) | 1.2 | 0.8 | −0.10 | 0.004 | 0.05 | 0.29 | 0.10 | 0.01 |
Hypochondriasis (0–4) | 1.0 | 0.9 | 0.04 | 0.27 | 0.22 | <0.001 | 0.22 | <0.001 |
Loss of weight (0–2) | 0.2 | 0.5 | −0.22 | <0.001 | −0.03 | 0.55 | −0.05 | 0.19 |
Insight (0–2) | 0.1 | 0.4 | −0.05 | 0.15 | 0.04 | 0.34 | 0.07 | 0.07 |
